Last reviewed · How we verify
prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur
Approved treatments
Clinical guidelines
- FDA label — adjuvant
TICE BCG is indicated for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur patent landscape — cliff calendar, originator estates, attackable patents
- prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur treatment landscape brief
- prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur treatment updates RSS
Frequently asked questions about prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur
What are the treatment guidelines for prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur?
FDA label publishes guidelines for prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur. 1 guideline references tracked.
Related
- Treatment landscape: prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur patent cliff · prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing